Ritholtz Wealth Management lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 12.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,899 shares of the biotechnology company’s stock after selling 8,690 shares during the quarter. Ritholtz Wealth Management’s holdings in Exelixis were worth $3,499,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in EXEL. BlackRock Inc. bought a new position in shares of Exelixis during the 2nd quarter worth about $1,581,991,000. Dimensional Fund Advisors LP increased its stake in Exelixis by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after acquiring an additional 39,920 shares during the period. Assetmark Inc. increased its stake in Exelixis by 1.7% in the first quarter. Assetmark Inc. now owns 3,388,920 shares of the biotechnology company’s stock valued at $145,351,000 after acquiring an additional 58,149 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Exelixis by 21.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,427,976 shares of the biotechnology company’s stock valued at $140,677,000 after acquiring an additional 429,505 shares during the period. Finally, Bank of America Corp DE increased its stake in Exelixis by 30.7% in the second quarter. Bank of America Corp DE now owns 2,149,397 shares of the biotechnology company’s stock valued at $116,949,000 after acquiring an additional 504,660 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.
Exelixis Price Performance
EXEL stock opened at $69.00 on Monday. The business has a fifty day moving average price of $62.29 and a 200 day moving average price of $52.23. Exelixis, Inc. has a fifty-two week low of $39.71 and a fifty-two week high of $73.69. The stock has a market capitalization of $16.84 billion, a price-to-earnings ratio of 20.66, a P/E/G ratio of 1.78 and a beta of 0.45.
Exelixis (NASDAQ:EXEL – Get Free Report) last announced its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.89 by $0.05. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The company had revenue of $658.70 million for the quarter, compared to analysts’ expectations of $646.51 million. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts expect that Exelixis, Inc. will post 3.42 earnings per share for the current fiscal year.
Analyst Ratings Changes
EXEL has been the subject of several recent research reports. Truist Financial increased their price target on shares of Exelixis from $54.00 to $60.00 and gave the stock a “hold” rating in a research report on Friday, October 30th. Stifel Nicolaus increased their target price on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 9th. Citizens Jmp boosted their price target on Exelixis from $55.00 to $65.00 and gave the company a “market outperform” rating in a research note on Monday, October 19th. Finally, Morgan Stanley lowered their price target on Exelixis from $60.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and a consensus price target of $58.62.
View Our Latest Research Report on Exelixis
Exelixis Company Profile
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Featured Stories
- Five stocks we like better than Exelixis
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
